A new resorbable magnesium scaffold for de novo coronary lesions, the DREAMS 3G: one-year results of the BIOMAG-1 first-in-human study

DOI: 10.4244/EIJ-D-23-00326

Michael Haude
Michael Haude1, MD; Adrian Wlodarczak2, MD; René J van der Schaaf3, MD; Jan Torzewski4, MD; Bert Ferdinande5, MD; Javier Escaned6, MD; Juan F Iglesias7, MD; Johan Bennett8, MD; Gabor G. Toth9, MD; Michael Joner10, MD; Ralph Toelg11, MD; Marcus Wiemer12, MD; Göran Olivecrano13, MD; Paul Vermeersch14, MD; Hector M. Garcia-Garcia15, MD; Ron Waksman15, MD
1. Medical Clinic I, Rheinland Klinikum Neuss GmbH, Lukaskrankenhaus, Neuss, Germany; 2. Department of Cardiology, Miedziowe Centrum Zdrowia SA, Lubin, Poland; 3. Department of Interventional Cardiology, OLVG, Amsterdam, the Netherlands; 4. Cardiovascular Center Oberallgäu-Kempten, Kempten, Germany; 5. Department of Cardiology, Ziekenhuis Oost Limburg (ZOL), Genk, Belgium; 6. Division of Cardiology, Hospital Clinico San Carlos IdISSC, Complutense University of Madrid, Madrid, Spain; 7. Cardiology Division, University Hospital of Geneva, Geneva, Switzerland; 8. Department of Cardiovascular Medicine, University Hospitals Leuven, Leuven, Belgium; 9. Division of Cardiology, Medical University Graz, Graz, Austria; 10. Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, München, Germany, and Deutsches Zentrum für Herz- und Kreislauf-Forschung (DZHK) e.V. Partner Site Munich Heart Alliance, Munich, Germany; 11. Cardiology Department, Heart Center Segeberger Kliniken, Bad Segeberg, Germany; 12. Department of Cardiology and Intensive Care, Johannes Wesling University Hospital, Ruhr University Bochum, Minden, Germany; 13. Department of Cardiology, Skåne University Hospital, Lund, Sweden; 14. Interventional Cardiology ZNA Middelheim, Antwerp, Belgium; 15. Interventional Cardiology, MedStar Washington Hospital Center, Washington, D.C., USA

Background: The third-generation coronary sirolimus-eluting magnesium scaffold, DREAMS 3G, is a further development of the DREAMS 2G (commercial name Magmaris), aiming to provide performance outcomes similar to drug-eluting stents (DES).

Aims: The BIOMAG-I study aims to assess the safety and performance of this new-generation scaffold.

Methods: This is a prospective, multicentre, first-in-human study with clinical and imaging follow-up scheduled at 6 and 12 months. The clinical follow-up will continue for 5 years.

Results: A total of 116 patients with 117 lesions were enrolled. At 12 months, after completion of resorption, in-scaffold late lumen loss was 0.24±0.36 mm (median 0.19, interquartile range 0.06-0.36). The minimum lumen area was 4.95±2.24 mm² by intravascular ultrasound and 4.68±2.32 mm² by optical coherence tomography. Three target lesion failures were reported (2.6%, 95% confidence interval: 0.9-7.9), all clinically driven target lesion revascularisations. Cardiac death, target vessel myocardial infarction and definite or probable scaffold thrombosis were absent.

Conclusions: Data at the end of the resorption period of DREAMS 3G showed that the third-generation bioresorbable magnesium scaffold is clinically safe and effective, making it a possible alternative to DES. ClinicalTrials.gov: NCT04157153.

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

bioresorbable scaffoldsdrug-eluting stentnstemistable angina
Read next article
Stepwise provisional versus systematic culotte for stenting of true coronary bifurcation lesions: five-year follow-up of the multicentre randomised EBC TWO Trial

Latest news